A randomized, double‐blind study to compare the efficacy and safety of nalbuphine nasal spray and injectable solution in patients after orthopaedic interventions and traumatological procedures

Author:

Tymko Volodymyr G.1,Tsapko Grigorii V.2,Filipenko Volodymyr A.3,Khvysiuk Oleksiy M.4,Kovalova Kateryna V.2,Kuznetsov Igor E.2ORCID

Affiliation:

1. Pharmaceutical company Microkhim Kyiv Ukraine

2. Clinical and Diagnostic Center Pharmbiotest Kyiv Ukraine

3. Sytenko Institute of Spine and Joint Pathology National Academy of Medical Sciences of Ukraine Kharkiv Ukraine

4. Regional Clinical Trauma Hospital Kharkiv Ukraine

Abstract

AimsOur previous 3‐period crossover study in healthy volunteers comparing the pharmacokinetics of nalbuphine nasal spray Apain with parenteral nalbuphine solution demonstrated high bioavailability of the nasal spray and close similarity of pharmacokinetic profiles after intranasal and intramuscular administration, especially within 30 min postdose. The aim of the present study was a noninferiority assessment of nalbuphine nasal spray vs. intramuscular injection for pain relief in postoperative patients.MethodsNinety orthopaedic and traumatology patients were enrolled in this double‐blind, randomized study of the effectiveness and tolerance of a single 10.5 mg dose of nalbuphine nasal spray vs. 10 mg intramuscular injection. The summed pain intensity difference (SPID0–6) calculated using visual analogue scale scores was the primary study endpoint.ResultsOf 90 subjects enrolled, the per‐protocol efficacy population comprised 79 patients; 6 patients in the reference group and 5 patients in the test group were excluded due to remedication. The mean values of study endpoints with 95% confidence interval were as follows in reference and test groups, respectively: SPID0–6 = 228.08 (205.73–250.43) vs. 248.73 9 (225.83–271.63), time to pain relief onset = 0.28 h (0.25–0.31) vs. 0.27 h (0.25–0.29), duration of analgesia = 5.55 h (5.17–5.93) vs. 5.51 h (5.10–5.92), area under the curve = 119.30 (91.17–147.43) vs. 99.81 (74.52–107.10). No statistically significant differences were revealed.ConclusionNalbuphine nasal spray Apain has been proven to be a safe, noninvasive alternative to intramuscular nalbuphine to relieve severe postoperative pain. Designed for self‐administration and dose‐adjusting, the noncontrolled opioid analgesic nalbuphine spray can be used for patient‐controlled analgesia in out‐of‐hospital, field and home settings.

Publisher

Wiley

Reference38 articles.

1. ForrestW.Report of the veteran's administration cooperative analgesic study. Proceedings of the 33rd Annual Scientific Meeting Committee on Problems of Drug Dependence National Academy of Science Washington DC.1971;239–281.https://link.springer.com/article/10.1007/BF00637566

2. A comparison of the analgesic effect of intramuscular nalbuphine and morphine in patients with postoperative pain;Beaver W;J Pharmacol Exp Ther,1978

3. Analgesic effect of intramuscular and oral nalbuphine in postoperative pain

4. A Comparision of Nalbuphine with Morphine for Analgesic Effects and Safety : Meta-Analysis of Randomized Controlled Trials

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3